TG Therapeutics Inc (STU:NKB2)
€ 15.004 -0.278 (-1.82%) Market Cap: 2.33 Bil Enterprise Value: 2.24 Bil PE Ratio: 74.36 PB Ratio: 15.79 GF Score: 73/100

TG Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 05:20PM GMT
Release Date Price: €30 (+0.40%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst

Hi. Good afternoon, everyone, and welcome to the 120 session of the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover both U.S. and European biopharma companies here at Goldman Sachs. It's my great pleasure to be hosting TG Therapeutics today in a fireside chat. And with that, let me welcome Company's CEO, Michael Weiss. Michael, how are you? Thanks for joining us.

Michael S. Weiss
TG Therapeutics, Inc. - Executive Chairman, CEO & President

Thanks for having me, appreciate it.

Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst

It's actually your second healthcare conference with us. And for those of you who may have joined last year, Michael, you may remember as well, we did our fireside chat. It was the very last day of the conference in the very last time slot. I was happy to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot